Abstract: The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.

Abstract: Embodiments of the present disclosure provide a coated film structure including a substrate layer, an overcoat layer, and at least one intermediate layer disposed between the substrate layer and the overcoat layer. The substrate layer includes a polymer film substrate, the overcoat layer includes an acid-functional copolymer, and the at least one intermediate layer includes aluminum oxide. The coated film structure has an oxygen transmission rate of less than about 3.00 cm3/m2/day at 50% relative humidity and 23° C. as measured in accordance with ASTM D3985. Further, the coated film structure has a water vapor transmission rate of less than 2.50 g/m2/day at 90% relative humidity and 37.8° C. as measured in accordance with ASTM E-398.

Abstract: A coated film with barrier properties can include a film comprising a layer selected from the group consisting of a polymer layer, vacuum applied coating, a printed layer, and a primer coating; an ethylene vinyl alcohol copolymer/ethylene acrylic acid copolymer blend (EVOH/EAA) barrier coating on the layer and comprising ethylene vinyl alcohol copolymer (EVOH) and ethylene acrylic acid copolymer (EAA) at a weight ratio of EVOH to EAA of 1.5:1 to about 6:1, wherein the EAA has an acrylic acid content of 10 wt % to 35 wt %; and wherein the coated film has percent reduction in oxygen transmission rate (23° C., 50% relative humidity) of 80% or greater relative to a same film without the EVOH/EAA barrier coating.

Abstract: The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.

Abstract: The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.

Abstract: Embodiments of the present disclosure provide a coated film structure including a substrate layer, an overcoat layer, and at least one intermediate layer disposed between the substrate layer and the overcoat layer. The substrate layer includes a polymer film substrate, the overcoat layer includes an acid-functional copolymer, and the at least one intermediate layer includes aluminum oxide. The coated film structure has an oxygen transmission rate of less than about 3.00 cm3/m2/day at 50% relative humidity and 23° C. as measured in accordance with ASTM D3985. Further, the coated film structure has a water vapor transmission rate of less than 2.50 g/m2/day at 90% relative humidity and 37.8° C. as measured in accordance with ASTM E-398.

Abstract: Embodiments of the present disclosure provide a coated film structure including a substrate layer, an overcoat layer, and at least one intermediate layer disposed between the substrate layer and the overcoat layer. The substrate layer includes a polymer film substrate, the overcoat layer includes polyvinyl alcohol, and the at least one intermediate layer includes aluminum oxide. The substrate layer has a thickness from 1 ?m to 120 ?m and the overcoat layer has a dry coat weight of from about 0.05 g/m2 to about 1.5 g/m2. The coated film structure has an oxygen transmission rate of less than about 0.70 cm3/m2/day at 90% relative humidity and 23° C. as measured in accordance with ASTM D3985. Further, the coated film structure has a water vapor transmission rate of less than 1.00 g/m2/day at 90% relative humidity and 37.8° C. as measured in accordance with ASTM E-398.

Abstract: The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.

Abstract: The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.

Abstract: Embodiments of the present disclosure provide a coated film structure including a substrate layer, an overcoat layer, and at least one intermediate layer disposed between the substrate layer and the overcoat layer. The substrate layer includes a polymer film substrate, the overcoat layer includes polyvinyl alcohol, and the at least one intermediate layer includes aluminum oxide. The substrate layer has a thickness from 1 ?m to 120 ?m and the overcoat layer has a dry coat weight of from about 0.05 g/m2 to about 1.5 g/m2. The coated film structure has an oxygen transmission rate of less than about 0.70 cm3/m2/day at 90% relative humidity and 23° C. as measured in accordance with ASTM D3985. Further, the coated film structure has a water vapor transmission rate of less than 1.00 g/m2/day at 90% relative humidity and 37.8° C. as measured in accordance with ASTM E-398.

Abstract: The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.

Abstract: The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.

Abstract: Embodiments of the present disclosure are directed to primer coatings, polymeric substrates, and methods of producing thereof, which provide enhanced adhesion and enhanced barrier properties. The primer coatings comprise an aqueous mixture of amorphous polyvinyl alcohol, an adhesion promoter comprising one or more of polyethylene and polyurethane, a crosslinker, and optionally, a catalyst. The coated polymeric substrates comprise a polymeric substrate and a coating dispersed over the polymeric substrate, where the coating dispersed over the polymeric substrate comprises amorphous polyvinyl alcohol, an adhesion promoter, and a crosslinker. The methods for making coated polymeric substrates comprise stretching a polymeric substrate, applying a coating of amorphous polyvinyl alcohol, an adhesion promoter, and a crosslinker to at least one surface of the stretched polymeric substrate, and curing the coating onto at least one surface of the stretched polymeric substrate.

Abstract: Lamination adhesives including an aqueous dispersion having a mixture of a polyamide and an ethylene acrylic acid copolymer are provided for use on a variety of substrates. In various embodiments, the aqueous dispersion is substantially free of plasticizers and non-aqueous organic solvents. Also provided is a method of forming a laminate adhesion between two substrates. The disclosure also describes a laminate structure comprising first and second substrates laminated together by the lamination adhesive, the lamination adhesive including a mixture of a polyamide and a copolymer of ethylene and acrylic acid.

Abstract: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.

Abstract: The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.

Abstract: The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.

Abstract: Lamination adhesives including an aqueous dispersion having a mixture of a polyamide and an ethylene acrylic acid copolymer are provided for use on a variety of substrates. In various embodiments, the aqueous dispersion is substantially free of plasticizers and non-aqueous organic solvents. Also provided is a method of forming a laminate adhesion between two substrates. The disclosure also describes a laminate structure comprising first and second substrates laminated together by the lamination adhesive, the lamination adhesive including a mixture of a polyamide and a copolymer of ethylene and acrylic acid.

Abstract: Primer coatings including an aqueous dispersion having a mixture of a polyamide and a copolymer of ethylene and acrylic acid are provided for use on a variety of substrates. In various embodiments, the aqueous dispersion is substantially free of non-aqueous plasticizers and organic solvents. Also provided is a method of coating a substrate, the method including applying an aqueous dispersion to the substrate and drying the aqueous dispersion on the substrate to form a coating on the substrate. The disclosure also describes a substrate coated with a primer layer including a mixture of a polyamide and a copolymer of ethylene and acrylic acid.